Novartis-GSK asset swap allows Valneva to take back control of marketing and distribution of Ixiaro

23 June 2015
2019_biotech_test_vial_discovery_big

France-based biotech company Valneva (EPA: VLA) is to take direct control over the marketing and distribution of Ixiaro, the travel vaccine against Japanese encephalitis.

This terminates the marketing and distribution agreement with UK pharma major GlaxoSmithKline (LSE: GSK) related to Ixiaro, signed in 2006 with Novartis'  (NOVN: VX) vaccines division. It has been possible due to specific contract provisions following the asset swap between Novartis and GSK, and supports Valneva’s strategy to build an independent and fully-integrated vaccines biotech company and use the potential of Dukoral, the company’s recently-acquired second travel vaccine.

It expects to significantly improve sales margins and profitability from Ixiaro. Valneva believes that it will be able to continue to grow in-market sales from current levels by giving it full focus and attention, and by entering markets where the vaccine is approved but not marketed. After a transition period expected to last until early 2016 in all major territories, Valneva will market and distribute the Japanese encephalitis vaccine through a combination of its own sales and marketing teams, and country-specific marketing and distribution arrangements with established local partners.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology